NCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
Clinical Trials
11 trialsNCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06188455 2024-01-03
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
The First Affiliated Hospital of Xiamen University
Phase 3 Not yet recruiting
NCT06081595 2023-10-13
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Fudan University
Phase 2 Not yet recruiting
NCT04068974 2021-03-16
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04590625 2020-10-19
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
Zhongshan Hospital Xiamen University
Phase 2 Unknown
NCT03587129 2020-08-05
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
First Affiliated Hospital of Harbin Medical University
Phase 2 Terminated
NCT03475589 2020-05-12
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
Sun Yat-sen University
Phase 4 Unknown
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT03393507 2018-01-16
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
The People's Hospital of Leshan
Phase 2 Unknown
NCT03298074 2017-09-29
Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer
Guangxi Medical University
Phase 2 Unknown